BENEFICIAL EFFECT OF METFORMIN AND NEBIVOLOL IN HIGH FAT DIET INDUCED OBESITY IN WISTAR RATS

• Author Information

  Siddhant Arora1 , Rakesh Sharma1 *, Divya Singh1 , Surbhi Jangir1 1Department of Pharmacology, Jaipur College of Pharmacy, Jaipur, Rajasthan

• Rakesh Sharma
• METFORMIN AND NEBIVOLOL

Abstract

This study evaluated the combined effects of metformin and nebivolol on high-fat diet (HFD)-induced obesity in Wistar rats, compared to the standard drug orlistat. Obesity, a chronic disease driven by genetic, environmental, and psychological factors, leads to significant health risks. HFD-fed rats showed increased body weight, glucose, triglycerides, and cholesterol levels, indicative of obesity and dyslipidemia. Metformin, an AMPK activator, and nebivolol, an antihypertensive agent, were administered individually and in combination from the fourth to the eighth week of HFD treatment. The combination therapy significantly reduced obesity markers such as body weight, BMI, Lee index, and feed intake more effectively than individual high-dose treatments. Additionally, it improved lipid profiles, decreasing LDL, triglycerides, and total cholesterol while increasing HDL levels. The study demonstrated that the combination of metformin and nebivolol is more effective in managing obesity than either drug alone, likely due to a synergistic effect on reducing feed intake and improving metabolic parameters. This provides a pharmacological basis for using a combination of metformin and nebivolol in treating obesity, highlighting their potential role in reducing body adiposity and improving overall metabolic health in obesity management. Keywords HFD-fed, Obesity, Arctium lappa, Metformin, etc.